NL301119I2 - Selinexor of een farmaceutisch aanvaardbaar zout ervan - Google Patents

Selinexor of een farmaceutisch aanvaardbaar zout ervan

Info

Publication number: NL301119I2
Authority: NL; Netherlands
Prior art keywords: selinexor; pharmaceutically acceptable; acceptable salt; salt; pharmaceutically
Prior art date: 2011-07-29

Application number

NL301119C

Other languages

English (en)

Other versions

NL301119I1 (nl

Original Assignee

Karyopharm Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-07-29

Filing date

2021-07-30

Publication date

2021-09-15

2021-07-30 Application filed by Karyopharm Therapeutics Inc filed Critical Karyopharm Therapeutics Inc

2021-08-04 Publication of NL301119I1 publication Critical patent/NL301119I1/nl

2021-09-15 Publication of NL301119I2 publication Critical patent/NL301119I2/nl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Virology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

NL301119C 2011-07-29 2021-07-30 Selinexor of een farmaceutisch aanvaardbaar zout ervan NL301119I2 (nl)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US201161513432P	2011-07-29	2011-07-29
US201161513428P	2011-07-29	2011-07-29
US201261610178P	2012-03-13	2012-03-13
US201261653588P	2012-05-31	2012-05-31
US201261654651P	2012-06-01	2012-06-01
PCT/US2012/048319 WO2013019548A1 (en)	2011-07-29	2012-07-26	Hydrazide containing nuclear transport modulators and uses thereof

Publications (2)

Publication Number	Publication Date
NL301119I1 NL301119I1 (nl)	2021-08-04
NL301119I2 true NL301119I2 (nl)	2021-09-15

Family

ID=46634546

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL301119C NL301119I2 (nl)	2011-07-29	2021-07-30	Selinexor of een farmaceutisch aanvaardbaar zout ervan

Country Status (36)

Country	Link
US (9)	US9079865B2 (nl)
EP (3)	EP3333164B1 (nl)
JP (3)	JP6005740B2 (nl)
KR (7)	KR20210083380A (nl)
CN (5)	CN103874690B (nl)
AR (1)	AR087342A1 (nl)
AU (6)	AU2012290454B2 (nl)
BR (1)	BR112014001934B1 (nl)
CA (1)	CA2842362C (nl)
CL (2)	CL2014000225A1 (nl)
CO (1)	CO6960539A2 (nl)
CY (2)	CY1119783T1 (nl)
DK (2)	DK2736887T3 (nl)
EA (1)	EA201490407A1 (nl)
ES (2)	ES2655645T3 (nl)
FR (1)	FR21C1042I2 (nl)
GE (1)	GEP201706616B (nl)
HK (2)	HK1198477A1 (nl)
HR (1)	HRP20180014T1 (nl)
HU (2)	HUE036058T2 (nl)
LT (2)	LT2736887T (nl)
LU (1)	LUC00219I2 (nl)
ME (1)	ME02936B (nl)
MX (1)	MX349712B (nl)
NL (1)	NL301119I2 (nl)
NO (1)	NO2021033I1 (nl)
PE (1)	PE20141170A1 (nl)
PL (2)	PL2736887T3 (nl)
PT (1)	PT2736887T (nl)
RS (1)	RS56823B1 (nl)
SI (1)	SI2736887T1 (nl)
SM (1)	SMT201800171T1 (nl)
TW (1)	TWI574957B (nl)
UA (1)	UA115532C2 (nl)
WO (1)	WO2013019548A1 (nl)
ZA (1)	ZA201401223B (nl)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2011109799A1 (en)	2010-03-05	2011-09-09	Karyopharm Therapeutics, Inc.	Nuclear transport modulatiors and uses thereof
AU2012207565B2 (en)	2011-01-17	2016-04-07	Karyopharm Therapeutics Inc.	Olefin containing nuclear transport modulators and uses thereof
KR20210083380A (ko)	2011-07-29	2021-07-06	카리오팜 쎄라퓨틱스, 인코포레이티드	하이드라지드 함유 핵 수송 조절인자 및 이의 용도
WO2013019561A1 (en) *	2011-07-29	2013-02-07	Karyopharm Therapeutics, Inc.	Nuclear transport modulators and uses thereof
US9649388B2 (en)	2012-01-18	2017-05-16	Bioneer Corporation	Magnetic nanoparticle-samirna complex and method for preparing same
EP3404027B1 (en)	2012-05-09	2020-03-04	Biogen MA Inc.	Nuclear transport modulators and uses thereof
JO3407B1 (ar)	2012-05-31	2019-10-20	Eisai R&D Man Co Ltd	مركبات رباعي هيدرو بيرازولو بيريميدين
CN112500338A (zh)	2013-03-15	2021-03-16	全球血液疗法股份有限公司	化合物及其用于调节血红蛋白的用途
US10202366B2 (en) *	2013-03-15	2019-02-12	Karyopharm Therapeutics Inc.	Methods of promoting wound healing using CRM1 inhibitors
WO2014205393A1 (en) *	2013-06-21	2014-12-24	Karyopharm Therapeutics Inc.	Nuclear transport modulators and uses thereof
LT3010892T (lt) *	2013-06-21	2019-04-10	Karyopharm Therapeutics Inc.	1,2,4-triazolai kaip branduolio transporto moduliatoriai ir jų panaudojimas
CN105705638B (zh)	2013-07-05	2019-11-26	柏业公司	改善的具有高效能的纳米颗粒型寡核苷酸结构及其制备方法
US9695421B2 (en)	2013-07-05	2017-07-04	Bioneer Corporation	Dengue virus-specific siRNA, double helix oligo-RNA structure comprising siRNA, and composition for suppressing proliferation of dengue virus comprising RNA structure
KR20150006743A (ko) *	2013-07-09	2015-01-19	(주)바이오니아	간암 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 암 예방 또는 치료용 조성물
EA201992707A1 (ru)	2013-11-18	2020-06-30	Глобал Блад Терапьютикс, Инк.	Соединения и их применения для модуляции гемоглобина
EP3074007B1 (en) *	2013-11-28	2019-07-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of beta-thalassemias
WO2015152693A2 (ko)	2014-04-04	2015-10-08	(주)바이오니아	신규 이중 나선 올리고 rna 및 이를 포함하는 섬유증 또는 호흡기 질환의 예방 또는 치료용 약학조성물
EA201790384A1 (ru) *	2014-08-15	2017-08-31	Кариофарм Терапевтикс, Инк.	Полиморфы селинексора
WO2017117529A1 (en)	2015-12-31	2017-07-06	Karyopharm Therapeutics Inc.	Nuclear transport modulators and uses thereof
EP3397634A1 (en)	2015-12-31	2018-11-07	Karyopharm Therapeutics, Inc.	Nuclear transport modulators and uses thereof
WO2017118940A1 (en) *	2016-01-08	2017-07-13	Dr. Reddy's Laboratories Limited	Solid forms of selinexor and process for their preparation
EP3241830A1 (de)	2016-05-04	2017-11-08	Bayer CropScience Aktiengesellschaft	Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
WO2018050801A1 (en)	2016-09-16	2018-03-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of systemic mastocytosis
US11602530B2 (en)	2016-11-28	2023-03-14	Biogen Ma Inc.	CRM1 inhibitors for treating epilepsy
US10993943B2 (en) *	2017-01-05	2021-05-04	Watson Laboratories Inc.	Crystalline forms of selinexor and process for their preparation
CN106831617A (zh) *	2017-01-17	2017-06-13	广州市闻皓生物科技有限公司	一种Selinexor中间体的合成工艺
CN106831731B (zh) *	2017-01-17	2019-11-08	广州市闻皓生物科技有限公司	一种Selinexor原料药的合成方法
WO2018191707A2 (en) *	2017-04-13	2018-10-18	Brown University	Nucleocytoplasmic regulator of autophagy-associated transcription factors
WO2019232724A1 (en) *	2018-06-06	2019-12-12	Xw Laboratories, Inc.	Compounds as nuclear transport modulators and uses thereof
CN108947982A (zh) *	2018-08-16	2018-12-07	刘璐	治疗非酒精性脂肪肝病的吡嗪衍生物、组合物和应用
WO2020092965A1 (en) *	2018-11-01	2020-05-07	Karyopharm Therapeutics Inc.	E2f1 as a biomarker for treatments using xpo1 inhibitors
CN111606890A (zh) *	2019-02-26	2020-09-01	微境生物医药科技(上海)有限公司	含丙烯酰基的核转运调节剂及其用途
KR20210141936A (ko)	2019-03-20	2021-11-23	존슨 맛쎄이 퍼블릭 리미티드 컴파니	셀리넥서의 공결정 형태
AU2020266170A1 (en)	2019-05-01	2021-11-25	Karyopharm Therapeutics Inc.	Process for preparing XPO1 inhibitors and intermediates for use in the preparation of XP01 inhibitors
EP3808742A1 (en)	2019-10-16	2021-04-21	Sandoz AG	Polymorph of selinexor
WO2021163338A1 (en)	2020-02-11	2021-08-19	Karyopharm Therapeutics Inc.	Xpo1 inhibitors for use in treating cancer
CA3171979A1 (en)	2020-03-27	2021-09-30	Josep Bassaganya-Riera	Plxdc2 ligands
WO2021202745A1 (en)	2020-03-31	2021-10-07	Karyopharm Therapeutics Inc.	Treatment of covid-19 with a sine compound
US20230218644A1 (en)	2020-04-16	2023-07-13	Som Innovation Biotech, S.A.	Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
WO2021252874A1 (en)	2020-06-11	2021-12-16	Karyopharm Therapeutics Inc.	Xpo1 inhibitors for use in treating cancer
WO2021252905A1 (en)	2020-06-11	2021-12-16	Karyopharm Therapeutics Inc.	Biomarkers for response to exportin-1 inhibitors in diffuse large b-cell lymphoma patients
WO2021252900A1 (en)	2020-06-11	2021-12-16	Karyopharm Therapeutics Inc.	Biomarkers for response to exportin-1 inhibitors in multiple myeloma patients
US20230391754A1 (en)	2020-10-21	2023-12-07	Karyopharm Therapeutics Inc.	Crystalline form of selinexor
CN112679477B (zh) *	2020-12-17	2021-10-26	佛山奕安赛医药科技有限公司	塞利尼索及其中间体的制备方法
WO2022143779A1 (zh) *	2020-12-29	2022-07-07	南京明德新药研发有限公司	含烯基类化合物及其应用
WO2022232417A1 (en)	2021-04-28	2022-11-03	Karyopharm Therapeutics Inc.	Biomarkers for response to exportin-1 inhibitors in multiple myeloma patients
WO2022246065A1 (en)	2021-05-19	2022-11-24	Karyopharm Therapeutics Inc.	Calb1 biomarker in the treatment of de-differentiated liposarcoma using xpo1 inhibitors, such as selinexor
WO2023172855A2 (en) *	2022-03-07	2023-09-14	Kaohsiung Medical University	Methods for treating hepatitis b virus infection
CN116514773B (zh) *	2023-04-24	2024-12-03	重庆汉佩生物科技有限公司	一种Verdinexor(KPT-335)及其盐酸盐的合成方法

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1017398A (en)	1911-01-16	1912-02-13	John E Folsom	Telegraph-key.
JPS5661360A (en) *	1979-10-25	1981-05-26	Teijin Ltd	1-substituted imidazole derivative and its preparation
CS229934B2 (en)	1981-07-07	1984-07-16	Pfizer	Production method subst.indolylacryte acid derivative
KR840000529A (ko)	1981-07-07	1984-02-25	콘스탄틴 루이스 클레멘트	인돌 유도체의 제조방법
US4778796A (en)	1985-07-19	1988-10-18	Dainippon Pharmaceutical Co., Ltd.	ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
JP3111321B2 (ja)	1990-02-23	2000-11-20	武田薬品工業株式会社	縮合チアゾール化合物
IL97249A (en) *	1990-02-23	1995-01-24	Takeda Chemical Industries Ltd	Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or
US5541213A (en)	1993-06-24	1996-07-30	Eisai Co., Ltd.	Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5468353A (en)	1994-05-05	1995-11-21	Minnesota Mining And Manufacturing Company	Mist suppressant for solvent extraction metal electrowinning
BR9509760A (pt)	1994-11-23	1998-06-30	Neurogen Corp	Composto
US20030018025A1 (en) *	1995-06-07	2003-01-23	Neurogen Corporation, Corporation Of The State Of Delaware	Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
EP0858457A1 (de)	1995-10-20	1998-08-19	Dr. Karl Thomae GmbH	5-gliedrige heterocyclen, diese verbindungen enthaltende arzneimittel und deren verwendung sowie verfahren zu ihrer herstellung
CA2250002C (en)	1996-04-04	2008-03-25	Shionogi & Co., Ltd.	Cephem compounds and drugs containing the compounds
JP4054992B2 (ja)	1996-04-25	2008-03-05	日産化学工業株式会社	エチレン誘導体および有害生物防除剤
ATE244219T1 (de)	1996-04-25	2003-07-15	Nissan Chemical Ind Ltd	Ethylenderivate und pestizide
DE19624659A1 (de)	1996-06-20	1998-01-08	Klinge Co Chem Pharm Fab	Neue Pyridylalken- und Pyridylalkinsäureamide
US5994398A (en)	1996-12-11	1999-11-30	Elan Pharmaceuticals, Inc.	Arylsulfonamides as phospholipase A2 inhibitors
JP4416198B2 (ja)	1997-12-19	2010-02-17	武田薬品工業株式会社	アニリド誘導体、その製造法および用途
AU2960599A (en)	1998-03-30	1999-10-18	Akira Karasawa	Quinazoline derivatives
CO5271680A1 (es)	2000-02-21	2003-04-30	Smithkline Beecham Corp	Compuestos
ES2257441T3 (es)	2000-09-29	2006-08-01	Topotarget Uk Limited	Compuestos de acido carbonico que comprenden un enlace amino como inhibidores hdac.
KR20100107509A (ko)	2001-09-14	2010-10-05	9222-9129 퀘벡 인코포레이티드	히스톤 데아세틸라아제의 억제제
WO2004037248A2 (en)	2002-10-24	2004-05-06	Carex Sa	Modulation of peroxisome proliferator activated receptors activity
DE10250743A1 (de)	2002-10-31	2004-05-19	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
TW200416029A (en)	2002-11-01	2004-09-01	Takeda Chemical Industries Ltd	Agent for preventing or treating neuropathy
JP4145230B2 (ja)	2002-11-01	2008-09-03	武田薬品工業株式会社	神経障害の予防・治療剤
AU2003291403A1 (en)	2002-11-08	2004-06-03	Neurogen Corporation	3-substituted-6-aryl pyridined as ligands of c5a receptors
EP1599447A1 (en)	2003-02-28	2005-11-30	Galderma Research & Development, S.N.C.	Ligands that modulate lxr-type receptors
EP1757591A4 (en)	2004-05-26	2010-05-05	Eisai R&D Man Co Ltd	ZIMTSÄUREAMIDVERBINDUNG
BRPI0515015A (pt)	2004-08-11	2008-07-01	Kyorin Seiyaku Kk	derivado cìclico de ácido aminobenzóico; medicamento; agonista ppar(alpha); agonista duplo ppar(alpha), y; agonista duplo ppar(alpha), (delta); modulador ppar; agente lipìdeo; agente profilático ou terapêutico compreendendo pelo menos um dos derivados cìclicos de ácido aminobenzóico ou sal do mesmo farmacêuticamente aceitável
WO2006019020A1 (ja)	2004-08-16	2006-02-23	Sankyo Company, Limited	置換されたウレア化合物
JPWO2006088246A1 (ja)	2005-02-18	2008-07-10	武田薬品工業株式会社	Ｇｐｒ３４受容体機能調節剤
TWI330639B (en)	2005-11-15	2010-09-21	Otsuka Pharma Co Ltd	Oxazole compound and pharmaceutical composition
JP2007210929A (ja)	2006-02-09	2007-08-23	Sankyo Co Ltd	ウレア化合物を含有する医薬
CA2643796A1 (en)	2006-03-09	2007-09-13	Eisai R & D Management Co., Ltd.	Polycyclic cinnamide derivatives
WO2007118137A1 (en)	2006-04-07	2007-10-18	Methylgene Inc.	Benzamide derivatives as inhibitors of histone deacetylase
ES2522291T3 (es)	2006-04-18	2014-11-14	Nippon Chemiphar Co., Ltd.	Agente activador para el receptor activado por el proliferador de peroxisomas
DE102006024024A1 (de) *	2006-05-23	2007-11-29	Bayer Healthcare Aktiengesellschaft	Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
US8653115B2 (en)	2006-06-13	2014-02-18	Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences	Heterocyclic non-nucleoside compounds, their preparation, pharmaceutical composition and their use as antiviral agents
CN100503571C (zh)	2006-07-12	2009-06-24	中国药科大学	四氢异喹啉类衍生物、其制备方法及其医药用途
WO2008013414A1 (en)	2006-07-27	2008-01-31	Amorepacific Corporation	Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
CN101511796B (zh)	2006-09-05	2012-05-09	协和发酵麒麟株式会社	咪唑衍生物
EP1942104A1 (en)	2006-12-20	2008-07-09	sanofi-aventis	Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
EP1939180A1 (en)	2006-12-20	2008-07-02	sanofi-aventis	Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
US7795457B2 (en)	2007-02-26	2010-09-14	Kosan Biosciences Incorporated	Carbamate compounds
EP2003118A1 (de)	2007-06-13	2008-12-17	Bayer Schering Pharma Aktiengesellschaft	Zimtsäurederivate als Modulatoren des EP2-Rezeptors
WO2010017545A2 (en)	2008-08-08	2010-02-11	Synta Pharamceuticals Corp.	Triazole compounds that modulate hsp90 activity
CN102480969A (zh)	2009-07-09	2012-05-30	科锐医疗有限公司	伤口愈合和瘢痕调制方法
WO2011069039A1 (en)	2009-12-04	2011-06-09	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Hydrazone and diacyl hydrazine compounds and methods of use
WO2011109799A1 (en) *	2010-03-05	2011-09-09	Karyopharm Therapeutics, Inc.	Nuclear transport modulatiors and uses thereof
AU2012207565B2 (en)	2011-01-17	2016-04-07	Karyopharm Therapeutics Inc.	Olefin containing nuclear transport modulators and uses thereof
KR20210083380A (ko) *	2011-07-29	2021-07-06	카리오팜 쎄라퓨틱스, 인코포레이티드	하이드라지드 함유 핵 수송 조절인자 및 이의 용도
WO2013019561A1 (en)	2011-07-29	2013-02-07	Karyopharm Therapeutics, Inc.	Nuclear transport modulators and uses thereof
WO2013020024A2 (en)	2011-08-03	2013-02-07	Karyopharm Therapeutics, Inc.	Maleimide compounds and methods of treatment
EP3404027B1 (en)	2012-05-09	2020-03-04	Biogen MA Inc.	Nuclear transport modulators and uses thereof
WO2014152263A1 (en)	2013-03-15	2014-09-25	Karyopharm Therapeutics Inc.	Exo olefin-containing nuclear transport modulators and uses thereof
US10202366B2 (en)	2013-03-15	2019-02-12	Karyopharm Therapeutics Inc.	Methods of promoting wound healing using CRM1 inhibitors
WO2014205393A1 (en)	2013-06-21	2014-12-24	Karyopharm Therapeutics Inc.	Nuclear transport modulators and uses thereof
LT3010892T (lt)	2013-06-21	2019-04-10	Karyopharm Therapeutics Inc.	1,2,4-triazolai kaip branduolio transporto moduliatoriai ir jų panaudojimas
US11567063B2 (en)	2013-11-15	2023-01-31	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Methods for assessing cell viability or predicting cell response to a treatment using cell movement
JP6631616B2 (ja)	2014-07-26	2020-01-15	ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド	ＣＤＫ阻害剤としての２−アミノ−ピリド［２，３−ｄ］ピリミジン−７（８Ｈ）−オン誘導体及びその使用
EA201790384A1 (ru)	2014-08-15	2017-08-31	Кариофарм Терапевтикс, Инк.	Полиморфы селинексора
WO2017117529A1 (en)	2015-12-31	2017-07-06	Karyopharm Therapeutics Inc.	Nuclear transport modulators and uses thereof
EP3397634A1 (en)	2015-12-31	2018-11-07	Karyopharm Therapeutics, Inc.	Nuclear transport modulators and uses thereof
WO2017118940A1 (en)	2016-01-08	2017-07-13	Dr. Reddy's Laboratories Limited	Solid forms of selinexor and process for their preparation
JP6765198B2 (ja)	2016-03-10	2020-10-07	パナソニック株式会社	潜熱蓄熱材及びそれを用いる蓄熱システム
US11602530B2 (en)	2016-11-28	2023-03-14	Biogen Ma Inc.	CRM1 inhibitors for treating epilepsy
US10993943B2 (en)	2017-01-05	2021-05-04	Watson Laboratories Inc.	Crystalline forms of selinexor and process for their preparation

2012
- 2012-07-26 KR KR1020217019908A patent/KR20210083380A/ko not_active Application Discontinuation
- 2012-07-26 RS RS20171350A patent/RS56823B1/sr unknown
- 2012-07-26 UA UAA201401886A patent/UA115532C2/uk unknown
- 2012-07-26 KR KR1020237008529A patent/KR20230042129A/ko not_active Application Discontinuation
- 2012-07-26 DK DK12743846.3T patent/DK2736887T3/en active
- 2012-07-26 PL PL12743846T patent/PL2736887T3/pl unknown
- 2012-07-26 KR KR1020147005654A patent/KR102022716B1/ko active IP Right Grant
- 2012-07-26 HU HUE12743846A patent/HUE036058T2/hu unknown
- 2012-07-26 JP JP2014522997A patent/JP6005740B2/ja active Active
- 2012-07-26 WO PCT/US2012/048319 patent/WO2013019548A1/en active Application Filing
- 2012-07-26 PE PE2014000139A patent/PE20141170A1/es active IP Right Grant
- 2012-07-26 TW TW101126934A patent/TWI574957B/zh active
- 2012-07-26 KR KR1020197011563A patent/KR102136768B1/ko active IP Right Grant
- 2012-07-26 CN CN201280047939.2A patent/CN103874690B/zh active Active
- 2012-07-26 CN CN201910734865.3A patent/CN110372673B/zh active Active
- 2012-07-26 SM SM20180171T patent/SMT201800171T1/it unknown
- 2012-07-26 BR BR112014001934-7A patent/BR112014001934B1/pt active IP Right Grant
- 2012-07-26 EA EA201490407A patent/EA201490407A1/ru unknown
- 2012-07-26 DK DK17189480.1T patent/DK3333164T3/da active
- 2012-07-26 KR KR1020207020507A patent/KR20200088518A/ko not_active Application Discontinuation
- 2012-07-26 CN CN202311190454.5A patent/CN117229268A/zh active Pending
- 2012-07-26 EP EP17189480.1A patent/EP3333164B1/en active Active
- 2012-07-26 AU AU2012290454A patent/AU2012290454B2/en active Active
- 2012-07-26 SI SI201231147T patent/SI2736887T1/en unknown
- 2012-07-26 MX MX2014001181A patent/MX349712B/es active IP Right Grant
- 2012-07-26 EP EP12743846.3A patent/EP2736887B1/en active Active
- 2012-07-26 PL PL17189480.1T patent/PL3333164T3/pl unknown
- 2012-07-26 EP EP23162715.9A patent/EP4234545A3/en active Pending
- 2012-07-26 CN CN201610414957.XA patent/CN106083827B/zh active Active
- 2012-07-26 ES ES12743846.3T patent/ES2655645T3/es active Active
- 2012-07-26 LT LTEP12743846.3T patent/LT2736887T/lt unknown
- 2012-07-26 AR ARP120102724A patent/AR087342A1/es active IP Right Grant
- 2012-07-26 PT PT127438463T patent/PT2736887T/pt unknown
- 2012-07-26 CN CN201910730981.8A patent/CN110372672B/zh active Active
- 2012-07-26 KR KR1020257000206A patent/KR20250008805A/ko active Search and Examination
- 2012-07-26 KR KR1020247013182A patent/KR20240060688A/ko not_active Application Discontinuation
- 2012-07-26 ES ES17189480T patent/ES2954991T3/es active Active
- 2012-07-26 GE GEAP201213396A patent/GEP201706616B/en unknown
- 2012-07-26 CA CA2842362A patent/CA2842362C/en active Active
- 2012-07-29 US US14/235,306 patent/US9079865B2/en active Active
2014
- 2014-01-29 CL CL2014000225A patent/CL2014000225A1/es unknown
- 2014-02-18 ZA ZA2014/01223A patent/ZA201401223B/en unknown
- 2014-02-27 CO CO14041777A patent/CO6960539A2/es active IP Right Grant
- 2014-03-19 US US14/219,638 patent/US8999996B2/en active Active
- 2014-11-27 HK HK14111981.2A patent/HK1198477A1/xx unknown
2015
- 2015-05-11 CL CL2015001257A patent/CL2015001257A1/es unknown
- 2015-06-10 US US14/735,853 patent/US9206158B2/en active Active
- 2015-11-13 US US14/940,310 patent/US9714226B2/en active Active
2016
- 2016-08-04 AU AU2016210682A patent/AU2016210682B2/en active Active
- 2016-09-07 JP JP2016174614A patent/JP6309057B2/ja active Active
2017
- 2017-06-21 US US15/629,307 patent/US10173987B2/en active Active
2018
- 2018-01-04 HR HRP20180014TT patent/HRP20180014T1/hr unknown
- 2018-01-17 CY CY20181100059T patent/CY1119783T1/el unknown
- 2018-03-13 JP JP2018044974A patent/JP6675431B2/ja active Active
- 2018-04-02 ME MEP-2017-303A patent/ME02936B/me unknown
- 2018-04-06 AU AU2018202441A patent/AU2018202441B2/en active Active
- 2018-11-28 US US16/203,181 patent/US10544108B2/en active Active
- 2018-12-10 HK HK18115824.0A patent/HK1256745A1/zh unknown
2019
- 2019-11-26 US US16/696,702 patent/US11034660B2/en active Active
2020
- 2020-05-12 AU AU2020203121A patent/AU2020203121B2/en active Active
2021
- 2021-05-14 US US17/321,029 patent/US11787771B2/en active Active
- 2021-07-30 NL NL301119C patent/NL301119I2/nl unknown
- 2021-07-30 LT LTPA2021007C patent/LTC2736887I2/lt unknown
- 2021-08-18 LU LU00219C patent/LUC00219I2/fr unknown
- 2021-08-26 HU HUS2100030C patent/HUS2100030I1/hu unknown
- 2021-09-06 NO NO2021033C patent/NO2021033I1/no unknown
- 2021-09-15 FR FR21C1042C patent/FR21C1042I2/fr active Active
- 2021-09-22 CY CY2021028C patent/CY2021028I1/el unknown
2022
- 2022-05-16 AU AU2022203265A patent/AU2022203265A1/en not_active Abandoned
2023
- 2023-09-11 US US18/244,659 patent/US20240279188A1/en active Pending
2024
- 2024-05-01 AU AU2024202868A patent/AU2024202868A1/en active Pending

Also Published As

Publication number	Publication date
EA201490407A1 (ru)	2014-05-30
JP6675431B2 (ja)	2020-04-01
ES2954991T3 (es)	2023-11-28
US10544108B2 (en)	2020-01-28
US20180127384A1 (en)	2018-05-10
CY1119783T1 (el)	2018-06-27
NL301119I1 (nl)	2021-08-04
ME02936B (me)	2018-04-20
CN110372673A (zh)	2019-10-25
KR102022716B1 (ko)	2019-09-18
CA2842362C (en)	2020-06-16
US20200339521A1 (en)	2020-10-29
FR21C1042I1 (nl)	2021-11-19
TW201311666A (zh)	2013-03-16
DK3333164T3 (da)	2023-09-18
US10173987B2 (en)	2019-01-08
US9206158B2 (en)	2015-12-08
CY2021028I2 (el)	2022-03-24
TWI574957B (zh)	2017-03-21
EP3333164B1 (en)	2023-06-07
EP4234545A2 (en)	2023-08-30
CO6960539A2 (es)	2014-05-30
US20220073478A1 (en)	2022-03-10
ES2655645T3 (es)	2018-02-21
CN103874690B (zh)	2016-07-06
PT2736887T (pt)	2018-01-15
US20160304472A1 (en)	2016-10-20
NZ719623A (en)	2017-12-22
LUC00219I2 (nl)	2022-10-07
HK1256745A1 (zh)	2019-10-04
AU2016210682A1 (en)	2016-08-18
DK2736887T3 (en)	2018-01-02
PE20141170A1 (es)	2014-09-16
EP3333164A1 (en)	2018-06-13
BR112014001934A2 (pt)	2017-02-21
US11787771B2 (en)	2023-10-17
UA115532C2 (uk)	2017-11-27
PL3333164T3 (pl)	2023-12-18
CA2842362A1 (en)	2013-02-07
JP6005740B2 (ja)	2016-10-12
LTC2736887I2 (nl)	2022-10-25
ZA201401223B (en)	2022-03-30
GEP201706616B (en)	2017-02-10
US9079865B2 (en)	2015-07-14
US8999996B2 (en)	2015-04-07
US20140364408A1 (en)	2014-12-11
KR20230042129A (ko)	2023-03-27
NZ621904A (en)	2016-05-27
HK1198477A1 (en)	2015-05-08
AU2020203121B2 (en)	2022-02-17
WO2013019548A1 (en)	2013-02-07
HUS2100030I1 (hu)	2021-09-28
US20240279188A1 (en)	2024-08-22
BR112014001934B1 (pt)	2020-12-15
LT2736887T (lt)	2018-02-12
MX2014001181A (es)	2014-07-14
US9714226B2 (en)	2017-07-25
KR102136768B1 (ko)	2020-07-23
HRP20180014T1 (hr)	2018-04-20
AU2018202441B2 (en)	2020-02-13
KR20190045399A (ko)	2019-05-02
CN110372673B (zh)	2023-10-03
KR20200088518A (ko)	2020-07-22
US20140235653A1 (en)	2014-08-21
KR20140066179A (ko)	2014-05-30
PL2736887T3 (pl)	2018-03-30
CN106083827A (zh)	2016-11-09
AU2022203265A1 (en)	2022-06-02
US20190330164A1 (en)	2019-10-31
SMT201800171T1 (it)	2018-07-17
CL2015001257A1 (es)	2015-09-21
NO2021033I1 (no)	2021-09-06
JP2014521652A (ja)	2014-08-28
CN117229268A (zh)	2023-12-15
KR20240060688A (ko)	2024-05-08
FR21C1042I2 (fr)	2022-09-02
CN110372672A (zh)	2019-10-25
JP2018111713A (ja)	2018-07-19
LTPA2021007I1 (nl)	2021-08-25
EP4234545A3 (en)	2023-09-06
CN110372672B (zh)	2023-09-29
CN106083827B (zh)	2019-09-17
CY2021028I1 (el)	2022-03-24
AU2016210682B2 (en)	2018-04-19
KR20250008805A (ko)	2025-01-15
EP2736887A1 (en)	2014-06-04
KR20210083380A (ko)	2021-07-06
HUE036058T2 (hu)	2018-06-28
JP6309057B2 (ja)	2018-04-11
AU2024202868A1 (en)	2024-05-23
US20150274698A1 (en)	2015-10-01
AU2012290454B2 (en)	2016-05-05
CL2014000225A1 (es)	2014-12-05
CN103874690A (zh)	2014-06-18
AU2012290454A1 (en)	2014-03-20
AU2020203121A1 (en)	2020-05-28
MX349712B (es)	2017-08-09
SI2736887T1 (en)	2018-04-30
US11034660B2 (en)	2021-06-15
JP2017036287A (ja)	2017-02-16
AR087342A1 (es)	2014-03-19
RS56823B1 (sr)	2018-04-30
EP2736887B1 (en)	2017-10-18
AU2018202441A1 (en)	2018-04-26

Publication	Publication Date	Title
NL301119I2 (nl)	2021-09-15	Selinexor of een farmaceutisch aanvaardbaar zout ervan
NL301276I2 (nl)	2024-06-24	omaveloxolon of een farmaceutisch aanvaardbaar zout daarvan
NL301131I2 (nl)	2021-10-25	pemigatinib of een farmaceutisch aanvaardbaar zout daarvan
NL301157I2 (nl)	2023-11-09	odevixibat of een farmaceutisch aanvaardbaar zout daarvan
NL301191I2 (nl)	2022-12-07	voxelotor of een tautomeer of farmaceutisch aanvaardbaar zout daarvan
NL301248I2 (nl)	2023-11-20	atogepant of een farmaceutisch aanvaardbaar zout daarvan
NL301201I2 (nl)	2022-12-07	Asciminib of een farmaceutisch aanvaardbaar zout daarvan, zoals asciminibhydrochloride
NL301291I2 (nl)	2024-10-30	sparsentan of een farmaceutisch aanvaardbaar zout daarvan
NL301084I2 (nl)	2021-01-28	remdesivir of een farmaceutisch aanvaardbaar zout of ester daarvan
NL301292I2 (nl)	2024-10-30	Iptacopan of een farmaceutisch aanvaardbaar zout daarvan
NL301253I2 (nl)	2024-01-10	mavacamten of een farmaceutisch aanvaardbaar zout daarvan
NL300901I2 (nl)	2017-11-16	pibrentasvir of een farmaceutisch aanvaardbaar zout daarvan
NL301234I2 (nl)	2023-07-26	maralixibat of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder maralixibatchloride
NL301187I2 (nl)	2022-08-04	Rimegepant of een farmaceutisch aanvaardbaar zout daarvan
NL301254I2 (nl)	2024-01-10	Futibatinib of een zout daarvan
NL301035I2 (nl)	2020-04-15	upadacitinib of een farmaceutisch aanvaardbaar zout daarvan
NO2021041I1 (no)	2021-09-20	remimazolam or a pharmaceutically acceptable salt thereof
FIC20230028I1 (fi)	2023-08-28	Deukravasitinibi tai sen framaseuttisesti hyväksyttävä suola
NL301294I2 (nl)	2024-11-18	Dasiglucagon of een farmaceutisch aanvaardbaar zout of solvaat daarvan, zoals dasiglucagon hydrochloride
NL300963I2 (nl)	2021-03-08	inotersen of een zout daarvan
NL301197I2 (nl)	2022-11-04	daridorexant of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder daridorexanthydrochloride
NO2022010I1 (no)	2022-04-07	ripretinib, or a pharmaceutically acceptable salt thereof
NL300900I2 (nl)	2017-11-16	glecaprevir of een farmaceutisch aanvaardbaar zout of ester daarvan
NL301006I2 (nl)	2020-04-14	Lorlatinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301280I2 (nl)	2024-08-01	Rezafungin of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder rezafunginacetaat